Showing results (151-160 of 194) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III TrialJoyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Molecular Cancer|October 7, 2024
Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitorsAnnapoorna Venkatachalam, Cristina Correia, Kevin L Peterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid TumorsAndrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
Gynecologic Oncology|May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F Liu, Niya Xiong, Robert M Wenham, et al.
Cancer Discovery|September 15, 2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer OrganoidsSarah J Hill, Brennan Decker, Emma A Roberts, et al.
The Lancet. Oncology|May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine|September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safetyAna Oaknin, Amit M Oza, Domenica Lorusso, et al.
Experimental Hematology & Oncology|June 23, 2025
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivityRachel M Hurley, Jill M Wagner, Arun Kanakkanthara, et al.
Therapeutic Advances in Medical Oncology|November 29, 2023
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft modelsGwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, et al.
Pageof 20